Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

2025 Issues

Slide, tissue block repository ties past to AI’s future

September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence. When U.S. military operations of all kinds were slashed or shuttered in 2008 under the Base Realignment and Closure federal initiative, a massive U.S. Army repository of slides and tissue blocks—including gross specimens dating back to the Civil War—came close to being one of the victims. It was housed at the Armed Forces Institute of Pathology, which had been targeted for closure. “When BRAC happened, and all of these Department of Defense facilities were closed, they didn’t know what to do with their pathology tissues,” says Mark D. Lyman, MD, Colonel, Medical Corps, U.S. Air Force, and director of the Joint Pathology Center (JPC), Silver Spring, Md. “There was even some discussion about throwing the repository away.”

How two labs took on in-house sequencing

December 2025—Bringing next-generation sequencing (NGS) in-house can be approached in two ways: a rapid, comprehensive implementation or a gradual, progressive build. Florida Cancer Specialists opted for a rapid approach, starting with a complex pancancer solid tumor panel, which facilitated the addition of smaller assays.

Working out AI validation and implementation

December 2025—The CAP Artificial Intelligence Committee is developing a guide for laboratories on implementing AI, covering the entire machine learning life cycle. While laboratories can begin using AI now, they must ensure full validation, even for FDA-approved tools, due to potential biases and population drift.

Respiratory season panels, subtypes, and a new Survey

December 2025—The absence of CDC surveillance data due to the government shutdown has created uncertainty about the severity and impact of the current respiratory virus season. While regional public health surveillance provides some insights, concerns remain about the potential for a severe season, exacerbated by vaccine hesitancy and changes in vaccine guidance. 

Privacy, cost, safety—drone use for patient samples

December 2025—Northwestern Medicine Delnor Hospital piloted a program using drones for transporting patient samples and blood products between the hospital and cancer center. The program, using Valqari drones, achieved a 100% success rate in delivering 303 packages without any damage or temperature fluctuations. 

Why and how lab curbed its CBC and diff orders

December 2025—Massachusetts General Hospital implemented a clinical decision support solution to reduce unnecessary CBC and differential orders, particularly for inpatients. The solution involved an interruptive alert that targeted daily, more than daily, and as-needed orders, recommending alternative orders like CBCs without differentials.

LIS vendors, lab experts on standards and stakeholders

December 2025—A roundtable discussion on laboratory information systems (LIS) focused on the application of AI in lab workflows. Participants emphasized the need for AI to be used as a targeted tool to augment human work, highlighting its potential in streamlining documentation, coding, and data extraction. 

Challenges, and opportunities, abound

December 2025—When this column comes out, it will be nearly the end of 2025. It’s a good time to think about the challenges we have been facing—and the opportunities we will have in the coming years to address them. The CAP is no stranger to challenges, and neither are its members. There’s a lot going on in the world and in the health care markets that directly affects what we do. I believe that if we face these challenges head-on, we can find ways to improve laboratory quality and our ability to care for patients, all while strengthening the CAP as an organization.